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Reduction of protein excretion by dimethyl sulfoxide in rats with
passive Heymann nephritis. Passive Heymann nephritis, a model of
immune complex nephritis, was produced in rats by injection of rabbit
antibrush border membrane vesicle antibodies to examine the effect of
treatment of epimembranous glomerulonephritis with dimethyl sulfox-
ide. Administration of DMSO twice a day, 5 days a week for 4 weeks
significantly reduced protein excretion in the autologous phase of the
model. This beneficial effect occurred in animals in which treatment
was started a day after administration of the antibody and persisted for
4 weeks after treatment was discontinued. Serum triglyceride concen-
trations were significantly decreased, whereas, BUN, serum cholester-
ol, and globulin levels were significantly, but not reproducibly, re-
duced. That DMSO did not reduce proteinuria to normal values in rats
treated after proteinuria was well established, but was able to reduce
proteinuria significantly. Treatment of normal rats and those with
nephrotoxic serum nephritis did not reduce protein excretion. Glomeru-
Ii of rats with passive Heymann nephritis treated with DMSO studied by
immunofluorescent microscopy appeared to have less fluorescence for
IgG than control rats, but these differences were not significant.
However, C3 deposits were significantly decreased in treated rats, but
only during the first week of the disease and in vitro C3 fixation was
also significantly reduced in glomeruli of rats that had been treated with
DMSO. There was very little effect on serum complement activity:
CH5O was reduced only on day 1 of treatment, whereas the alternate
pathway activity and serum C3 concentration were unaffected. DMSO
may therefore reduce protein excretion, in part, by inhibiting C3-
dependent proteinuria. These studies indicate that DMSO is capable of
significantly reducing protein excretion in rats with passive Heymann
nephritis and that its action may involve reduction of complement
deposition within the glomeruli during the heterologous phase. Toxic
effects included a 2.5% mortality and decreased weight gain while being
treated with larger doses of DMSO. Treatment with a much smaller
dose succeeded in reducing proteinuria significantly without affecting
weight gain. There was no evidence of drug-induced liver or renal
damage.
Diminution de l'excrétion protéique par du dimethyl sulfoxide chez des
rats avec une néphrite passive de Heymann. La nCphrite passive de
Heymann, un modele de nephrite a complexes immuns a etC produite
chez des rats par injection d'anticorps anti-vCsicule de bordure en
brosse membranaire de lapin afin d'examiner l'effet du traitement de Ia
glomCrulonCphrite extramembraneuse par du dimethyl sulfoxyde. L'ad-
ministration de DMSO deux fois par jour, Sjours par semaine pendant 4
semaines a significativement diminué l'excrCtion protCique lors de Ia
phase autologue du modèle. Cet effet bénefique est survenu chez les
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animaux chez lesquels le traitement avait été dCmarré un jour apres
l'administration de l'anticorps, et a persisté pendant 4 semaines après
que le traitement ait Cté arrété. Les concentrations de triglycerides
sériques étaient significativement diminuées, alors que BUN, les ni-
veaux de cholesterol et de globulines sériques étaient significativement
mais non de facon reproductible, diminuCs. Que le DMSO n'a pas réduit
Ia protéinurie aux valeurs normales chez les rats traités apres que Ia
protéinurie soil bien établie, mais était capable de diminuer significati-
vement Ia protéinurie. Le traitement de rats normaux et de ceux avec
une nephrite sCrique néphrotoxique n'a pas diminué l'excrétion protCl-
que. Les glomerules de rats atteints de néphrite passive de Heymann
traitCs par du DMSO étudiés en microscopie par immunofluorescence
paraissaient avoir moms de fluorescence pour l'IgG que les contrôles,
mais Ia difference n'était pas significative. Toutefois, les dépôts de C3
Ctaient significativement diminués chez les rats traitCs, mais seulement
pendant Ia premiere semaine de Ia maladie, et Ia fixation in-vitro de C3
Ctait egalement réduite dans les glomerules de rats qui avaient etC
traités par le DMSO. Il y avait trés peu d'effet sur l'activité des
complements seriques: CH5O Ctait rCduit seulement lors du jour I de
traitement, tandis que l'activitC de Ia voie alterne et Ia concentration
sCrique de C3 n'Ctaient pas affectées. Le DMSO pourrait de Ia sorte
rCduire l'excrétion protCique, en partie en inhibant Ia protéinurie
dCpendante du C3. Ces etudes indiquent que le DMSO est capable de
rCduire significativement l'excrétion protCique chez des rats avec une
néphrite passive de Heymann, et que cette action pourrait mettre enjeu
une reduction de dépôts du complement dans les glomCrules pendant Ia
phase hétCrologue. Les effects toxiques comprenaient une mortalitC de
2,5% et une diminution de La prise de poids pendant le traitement avec
les plus fortes doses de DMSO. Le traitement avec une dose beaucoup
plus petite était efficace pour réduire Ia proteinurie significativement
sans affecter laprise de poids. II n'y avait pas de preuve d'une lesion
hepatique ou rCnale induite par Ic médicament.
Membranous nephropathy is a chronic glomerular disease
with a characteristic histopathological picture and, in the major-
ity of patients, the features of the nephrotic syndrome [1, 21.
The course varies considerably; about 25%of the patients remit
spontaneously and approximately 40% die from renal or other
causes within 15 years of onset [3, 4]. The results of treatment
have been controversial and unsatisfactory. Treatment with
corticosteroids, cytotoxic drugs, or azathiopi-ine has usually
been unsuccessful [5—8]. With few exceptions [9, 101, most
successful reports of treatment of this condition have been
based on uncontrolled and, often retrospective, studies [11—13].
Despite the availability of an animal model of membranous
glomerulopathy, Heymann nephritis [14—17], there have been
very few reports of treatment of rats with this disorder [18—20]
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to our knowledge. Our decision to study the effect of dimethyl
sulfoxide (DMSO) on experimentally induced membranous
glomerulonephritis was based on reports in which promising
results were obtained in the treatment of human [2 1—23] and
murine amyloidosis [24, 251 with DMSO. The demonstration of
reduced antireceptor antibody titers in mice with myasthenia
gravis [261 suggested that DMSO might be of potential value in
the treatment of an immunologically mediated disorder such as
membranous glomerulopathy.
The purposes of this report are to describe the finding of a
significant reduction in urine protein excretion in rats with
passive Heymann nephritis treated with DMSO and to describe
the results of studies directed at ascertaining the mechanism
whereby this beneficial effect is achieved.
Methods
Preparation of brushborder membrane antigen
Brushborder membrane (BBM) vesicles were isolated from
male Sprague-Dawley rats weighing 225 to 250 g using the
method of Booth and Kenny [271. After decapitation, the
kidneys were placed in cold saline and their cortices were
carefully removed. The cortices were homogenized in 10 mii
Tris-HC1, pH 7.10, 10 ml/g of cortex, at 4°C, 2000 rpm, five
strokes (Tri-R Instruments, model K41 homogenizer, Rockville
Center, New York). Magnesium chloride (1 M) was added to
give a concentration of 10 m of MgCl2 and the mixture was
stirred occasionally for 15 mm at 4°C. The preparation was then
centrifuged at x l000g for 10 mm in a centrifuge (model J-21B,
Beckman Instruments, Inc., Fullerton, California) at 4°C. The
pellet containing glomeruli and large fragments of tissue was
discarded. The supernatant was pelleted by spinning at
x 16000g for 12 mm. The pale pink region at the top of the pellet
was removed and resuspended in 5 ml/g cortex of 10 mM
mannitol-2 ifiM Tris-HCI, pH 7.10, and treated again with 1 M
MgC12 added as before to a final concentration of 10 m. After
stirring the mixture at 4°C for 15 mm, two short centrifugations
were done: the first at x l500g for 12 mm and the resulting
supernatant was then spun at x 17500g for 12 mm. The final
pellet was washed three times in cold isotonic saline (x24000g,
10 mm each) and then resuspended in 3 ml saline. The prepara-
tion was stored at —70° C or used immediately for immuniza-
tion. The concentration of BBM-protein was evaluated by the
Lowry assay for protein [281.
Alkaline phosphatase (Kit 14987, Boehringer Mannheim),
NatKATPase [29], succinic-cytochrome C reductase [30],
and maltase [31] were assayed to determine the purity of the
brushborder membrane fraction.
Preparation of antiserum
Antiserum to rat BBM was raised in New Zealand male white
rabbits. Initial immunization consisted of the intradermal injec-
tion of 7mg of rat BBM protein emulsified in an equal volume of
Freund's complete adjuvant. The antigen was divided into four
injections of 0.5 ml each. This procedure was repeated once a
week for 6 weeks, then the specific antibody production was
evaluated by double immunodiffusion and measured by an
immunoprecipitation method. The rabbits were boosted twice a
month and bled once a week; their sera were pooled.
Before use, the rabbits' serum was heat inactivated (56°C, 30
mm) and the antibody activity for rat blood elements was
removed by absorption with packed blood cells of normal rats.
Preparation of nephrotoxic serum
Nephrotoxic serum was prepared in New Zealand male white
rabbits as described previously [32].
Urine and serum studies
Twenty-four hour urine collections were performed using
metabolic cages without food but with water available ad
libitum. The total protein content of the urine was determined
using 3% sulfosalicylic acid [33]. The urine collections were
performed before induction of the disease, then before starting
treatment, and subsequently at 1- to 2-week intervals while
dimethyl sulfoxide was being given, and at similar intervals
after the chemical was discontinued. Serum samples obtained
after sacrifice were assayed for BUN, creatinine, total protein,
albumin, triglycerides and cholesterol concentrations, and for
SGPT and SGOT by standard laboratory techniques. Serum
IgG concentrations were measured by radial immunodiffusion.
CH5O [34], alternate pathway of complement [35], and serum
C3 concentrations [36] were measured in serum that had been
frozen at —70°C.
Rat anti-rabbit antibody responses
The serologic immune response of rats toward the infused
rabbit antiserum was measured as the amount of immune
complexes formed following in vitro interaction of samples
from these rats with rabbit IgG or normal rabbit serum. Rabbit
IgG was prepared by ammonium sulfate precipitation and
reconstituted in normal saline to a concentration of 500 mgldl.
The assay method for immune complexes was that of
Creighton, Lambert, and Miescher [37]. One hundred microli-
ters of serum samples from rats were mixed with 100 d of
normal rabbit serum or rabbit IgG preparations. These mixtures
were incubated at 37°C for 60 mm and at 4°C for 60 mm to allow
for the formation of immune complexes. After the completion
of these incubations, 600 .ti of polyethylene glycol-6000 (PEG)
in borate buffer (0.2 M, pH 8.4) was added so that the final
concentration of PEG was 4% (wlv). Following an overnight
incubation at 4°C to allow precipitation of immune complexes,
each sample was washed three times with 4% PEG in borate
buffer and spun down in a refrigerated centrifuge. The precipi-
tates were solubilized with a normal saline solution and their
protein contents were measured with a dye-binding assay (Bio-
Rad protein assay, Bio-Rad Laboratories, Richmond,
California).
These studies were done on serum from normal rats as well as
from saline-treated control rats with PHN and sera from
DMSO-treated rats with PHN during the autologous phase, that
is, on day 28 after induction. To evaluate levels of endogenous
complexes in each serum sample, assays were also performed
with the addition of 100 jil borate buffer substituting for the 100
1d of normal rabbit serum or IgG. As controls for the assay
procedure, studies were also conducted with normal rabbit
serum or IgG without the addition of any rat serum.
Histologic studies
Renal tissue samples were obtained at death for immunofluo-
rescent microscopy, snap-frozen in isopentane chilled with dry
ice, and cut in a cryostat (6 i). Sections were stained with
fluorescein-isothiocyanate conjugated-IgG fractions of mono-
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specific goat anti-rabbit IgG, rabbit anti-rat IgG, and goat anti-
rat C3 (N. L. Cappel Laboratories, Inc., Cochranville,
Pennsylvania).
Brushborder vesicles were examined by electron microsco-
py. Samples were fixed with 2.5% (v/v) glutaraldehyde in 0.1 M
sodium phosphate buffer (pH 7.5) containing 0.5% NaCl,
washed with the same buffer, postfixed with buffered 2% (w/v)
0S04 (pH 7.5). Ultrathin sections were examined in an electron
microscope (Phillips 201). Renal tissue sections for ultrastruc-
tural studies were prepared in the same way.
in vitro complement fixation
In vitro fixation of complement was studied by determining
whether glomeruli from control and treated rats with PHN were
able to fix human C3, and whether the addition of DMSO to
normal human serum influenced human C3 fixation. Renal
tissue samples from PHN rats treated for 1, 4, and 7 days were
processed as described above and incubated for 30 mm with
normal human serum, heat-inactivated normal human serum
(56°C for 30 mm), and normal human serum plus 0.1%, 1% or
5% DMSO. The slices were then stained with goat antihuman
C3 fluoresceinated antibody (Kallestad Labs Inc., Austin,
Texas). Three slides from untreated PHN rats with 4+ fluores-
cence for rat C3 were stained directly with antihuman C3 as an
additional control.
Statistical analysis
Statistical significance was determined by Student's t test.
The Wilcoxon rank sum test was used when the distribution of
the results was nonparametric, as in the case of the 24-hr urine
protein determinations.
induction of passive Heymann nephritis (PHN)
Two protocols were used for the production of PHN.
Protocol A. Twelve male Sprague-Dawley rats (150 to 175 g)
were given two injections (I and 1.5 ml; approximately 20 mg
IgG) of serum containing the specific rabbit antirat brushborder
membrane antibodies 1 hr apart via a tail vein. Six control rats
were injected with an equal volume of normal rabbit serum.
Urine protein excretion was measured and histological studies
were done during the heterologous phase (week 1) and at the
beginning of the autologous phase (week 2).
Protocol B. In a second group of rats (90 to 100 g) two
intravenous injections (0.5 and 1.0 ml) instead of one of the
rabbit anti-rat BBM serum were given 1 hr apart and then, 4
weeks later they were boosted with 1.5 ml serum i.v. and 1.5 ml
serum i.p. Urine protein excretion was measured and histologi-
cal studies were carried out 6 weeks after the first two injec-
tions. At this time, the rats were in the autologous phase of the
disease.
Induction of nephrotoxic serum nephritis (NTS)
To produce moderate nephritis, half the usual dose of rabbit
nephrotoxic serum was given intravenously in a dose of 0.5 ml
serum per 150 g of rat.
Study design
Male Sprague-Dawley rats were allowed free access to water
and rat chow (Ralston Purina, St. Louis, Missouri). Only water
Table 1. Experimental design
Group
Induction
of PHN
Onset of DMSO
treatment DMSO (40%) regimen
I Protocol A I day after induction
of PHN
2 ml (4 mg/g), i.p.,
twice daily, 20 daysa
2 Protocol A I day after induction
of PHN
3 ml (5 mg/g), i.p.,
twice daily, 30 days°
3 Protocol A 1 day after induction
of PHN
2 ml (4 mg/g), i.p.,
twice daily for 1, 4,
or 7 days
4 Protocol B 14 days after boost-
er injections, that
is, 6 weeks after
initial injections
2 to 3 ml (4 mg/g), i.p.,
twice daily for 21
days
5 Protocol A 1 day after induction
of PHN
0.5 mg/g, i.p., twice
daily for 28 days
° The
weekends.
dosage specified was administered 5 days/week, excluding
was allowed during the periods of urine collection in metabo-
lism units (Econo, Canlab, Montreal, Canada). The rats were
studied in four groups as shown in Table 1. Control rats
receiving normal saline were studied with each group receiving
DMSO.
Group 1. Twenty-four rats were randomly divided into treat-
ment and control cohorts 1 day after induction of PHN per
Protocol A. Twelve rats were given DMSO (Fisher Scientific
Co., Fair Lawn, New Jersey) in a dose of 2 ml (40% solution)
i.p. twice daily for 20 days; the control rats received 0.85%
saline by the same regimen. On day 21, six rats were chosen
randomly from each group and were sacrificed. Serum and
renal tissue samples were obtained for studies listed above. The
remaining six rats in each group were followed for another 21
days without treatment.
Group 2. Twenty rats were randomly assigned to either the
treatment or control regimens the day after PHN was induced
(Protocol A). These rats were treated with a larger dose of
DMSO (3 ml, 40% twice daily for 30 days). All the group 2 rats
were followed for a further 30 days without treatment before
they were killed.
Group 3. Passive Heymann nephritis was induced by Proto-
col A in a further group of 36 rats; 18 were injected with DMSO
and the remainder served as control rats. Groups of 12 rats (6
treated, 6 controls) were killed 2, 5, and 8 days after induction
of PHN (corresponding to 1, 4, and 7 days of treatment).
Kidney tissue samples were studied for deposition of rabbit
IgG, rat IgG, and rat C3. Kidney slices were also studied for in
vitro fixation of human C3.
Group 4. The experiment was modified in this group to
determine whether urine protein excretion would be reduced
after the PHN was well established. To this end, Protocol B was
used for induction of PHN in 12 rats. Rats with comparable
protein excretion were paired prior to starting treatment, then
six rats were treated with DMSO and six rats were given saline.
The details of the treatment regimens are summarized in Table
Three additional groups were studied:
Group V. Twenty rats with PHN (Protocol A) were assigned
to two cohorts and DMSO (40%) was given twice daily (0.5
mg/g body weight, i.p.) to rats in the experimental subset and
saline was given to the controls to determine whether a signifi-
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cant reduction in proteinuria could be produced without a
significant decrease in weight gain. Urine protein excretion was
measured 14 and 24 days after induction of PHN. The rats were
weighed before induction at 14 and 28 days.
Group 6. Thirty nephrotoxic serum nephritic rats were ran-
domly divided into treatment and control subgroups 1 day after
induction of nephrotoxic serum nephritis. Eighteen rats were
given DMSO 40% in a dose of 4 mglg i,p. twice daily for 21
days; the 12 control rats received 0.85% saline in the same
regimen. These nephrotoxic serum nephritic rats were studied
to see whether the observed reduction in proteinuria induced by
DMSO was specific to the passive Heymann model.
Group 7. Twenty-four normal rats were divided into two
groups to determine whether DMSO altered protein excretion
in normal rats either by interfering with the measurement of
protein in the urine or by some nonspecific, nonimmunologic
mechanism. Twelve rats were given DMSO 40% 5 mglg body
weight i.p. twice daily for 21 days. Control rats received saline.
Urine protein excretion was measured before and then after 14
and 21 days of treatment.
Results
Isolation of brushborder membrane vesicles
The quality of this technique for isolating BBM was assessed
by assaying three enzymes to determine the degree of enrich-
ment of the final pellet by BBM and by examining the contents
of the pellet by electron microscopy. Alkaline phosphatase and
maltase were used as markers for BBM, Na-K-ATPase was
used for the antiluminal membrane, and mitochondrial contami-
nation was assessed by measurement of succinic-cytochrome C
reductase activity. Results have been expressed as the relative
specific activity of each enzyme in the pellet containing purified
BBM compared with the crude cortical homogenate. The
relative specific activity (purified BBM/crude homogenate) of
enzymes (expressed as unit per milligram of protein fraction of
BBM) was maltase 10, alkaline phosphatase 8, Na-K-
ATPase 2 and succinic-cytochrome C reductase 0.1. The pellet
contained microvilli, but there was also some contamination.
This interpretation was supported by the ultrastructural obser-
vations revealing mainly elongated (0.5 to 1.0 ji), and smaller,
oval vesicles (0.2 to 0.5 i) typical of microvilli in different
stages of vesicularization. A few lysosomes and some debris
were also seen.
Immunodtfusion
Our rabbit anti-BBM antiserum and sheep anti-Fx1A antise-
rum (kindly provided by Dr. David Salant, Boston University
Medical Center, Boston, Massachusetts) revealed identical
antigenic components. Single lines of precipitation occurred
with both antisera, a thin line with the rabbit anti-BBM antise-
rum and a coarser one with the sheep anti-Fx1A antiserum. No
reaction was seen between normal rabbit serum IgG and BBM
antigen.
Localization of heterologous antibodies
Frozen sections of normal rat kidney were incubated with
rabbit anti-rat BBM antiserum and then stained by indirect
immunofluorescence using fluorescein labelled goat anti-rabbit
IgG. Markedly positive fluorescence was seen on only the
luminal surface of the proximal tubules. This indicated that the
rabbit anti-rat BBM antiserum was directed specifically against
the brush border.
Induction of passive Heymann nephritis
Proteinuria. Normal Sprague-Dawley rats aged 6 to 8 weeks
excrete under 5 mg protein per 24 hr. In our early studies, rats
in whom PHN was induced by Protocol A excreted 14.5 mg
proteinl24 hr (range, 2.9 to 49.0 mg) within 24 hr of inducing
PHN compared with 1.7 mg124 hr (range, 0.8 to 1.9 mg) for rats
given normal rabbit serum. A week later, the experimental rats
excreted 3.8 mg/24 hr and the control rats, 2.2 mg124 hr. Two
weeks after the induction of PHN, experimental rats excreted
31 mg/day (range, 12.2 to 64.0 mg) and control rats excreted 5.5
mg/24 hr (range, 1.8 to 9.2 mg). Therefore, two phases of
protein excretion were studied. During 2 years, the rabbits
produced antiserum that became increasingly potent with the
result that in more recent studies, the mean protein excretion of
rats with PHN, on day 28 for example, has ranged from 60.0 to
661.0 mg/24 hr with a mean SEM of 275.7 66.8 mg/24 hr.
Rats in whom PHN was induced by Protocol B excreted 63.5
mg of protein/24 hr (range, 10.1 to 237.8 mg) by day 30. Control
rats excreted less than 10 mg of protein/24 hr by day 30.
Histological studies. After 3 hr, but more so by 24 hr after
administration of the antiserum, weak, but definite, granular
deposits staining for rabbit IgG were seen all along the glomeru-
lar capillary walls, but not in the mesangium or brush borders of
the tubules. The intensity of staining as well as the number and
size of the deposits increased by day 14. In addition, from day
14, the same distribution and intensity of positive staining for
rat IgG were observed. No fluorescence was seen in the
sections from control rats.
By 24 hr, and to a greater extent after 14 days (Fig. 1), there
were numerous electron dense deposits in the lamina rara
externa and the subepithelial area of the glomerular basement
membrane. Foot process effacement was also apparent.
Results of treatment of nephritic rats with DMSO
Proteinuria. Protein excretion measured before induction of
PHN ranged from 0.7 to 1.4 mg/24 hr. In group 1, the rats
treated with DMSO had significantly less proteinuria than the
control rats on days 7, 14, and 21 (Fig. 2). However, although
the untreated rats continued to excrete more protein than the
previously treated animals on days 31 and 42, these differences
were no longer significant. Group 2 rats treated with DMSO for
a longer period excreted significantly less proteinl24 hr than
control rats during treatment. This significant difference persist-
ed for the duration of the month after DMSO had been
discontinued (Fig. 3).
Group 4 rats were treated with either DMSO or saline after
proteinuria had been established (Fig. 4). Before onset of
treatment, the experimental rats excreted 51.3 14.3 mg/24 hr
compared with the excretion of 45.6 10.9 mg/24 hr (P> 0.1)
from control rats. Two weeks after onset of treatment, the
treated rats excreted less protein than the control rats, but these
results were not significant. At 2 weeks, the values for experi-
mental and control rats were 85.4 26 versus 141.9 52.9
mg/24 hr. A significant (P < 0.05) reduction in proteinuria
occurred after 3 weeks of treatment. The experimental rats
excreted 47.6 8.9 mg!24 hr protein versus the excretion of
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Fig. 1. Ultrastructura! appearance of the lesion at 14 days. Many subepithelial deposits are seen and some are indicated by the arrows. The
overlying epithelial cells show fusion of their major foot processes. (x4,950)
'.t.e
•••t.;
•it• ¼:1::
$•.,;. 4/.
,,- •y_4
•1.
'1
Reduction of proteinuria by DMSO 783
Time, days
P = NS <0.01 <z 0.05 <0.01 NS NS
Fig. 2. Protein excretion of rats in group 1. The results are expressed
as mean SEM. The Wilcoxon rank sum test was used to analyze the
results. Differences were significant when P < 0.05. Symbols are:I—•, control rats; •---•, experimental rats.
94.8 24.3 mg/24 hr by the control animals. Three weeks after
cessation of treatment, urine protein excretion was almost the
same in the previously treated rats and the control rats; 114.0
versus 120.5 mg/24 hr. When this experiment was repeated,
similar results were obtained. Before treatment with DMSO,
urine protein excretion was 325.0 mg124 hr in experimental rats
and 314.0 mg!24 hr in control rats; after 6 weeks of treatment,
urine protein excretion decreased to 184.0 mg124 hr; control rats
excreted 405.0 mg124 hr. This difference was highly significant
(P < 0.005).
Rats treated with 0.5 mg DMSO/g rat had a significant
reduction in protein excretion on days 14 and 28 compared with
control rats (Table 2). However, in contrast to rats treated with
higher doses of DMSO, the reduction in proteinuria was not
accompanied by a deleterious effect on weight gain (Table 2).
In the rats with nephrotoxic serum nephritis (group 6), there
was no significant difference in the excretion of protein between
treated and control rats on days 8, 15, and 23. The results were
(mean SEM, treated versus control); day 8, 27.9 8.7 versus
24.8 6.6; day 15, 12.8 3.4 versus 14.5 6.8; day 23, 16.3
3.5 versus 22.3 6.9 mg/24 hr.
The results of normal rats treated with DMSO did not reveal
significant effect on protein excretion compared with untreated
normal control rats (Table 3).
Time, days
<0.01
<0.01 < 0.01 < 0.01 <0.01 <0.01
Fig. 3. Protein excretion of Heymann nephritic rats in group 2. The
results are expressed as mean SaM. The Wilcoxon rank sum test was
used to analyze the results. Differences were significant when P < 0.05.
Symbols used are the same as those used for Figure 2.
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Fig. 4.Protein excretion of rats in group 4. The results are expressed as
mean SEM. The Wilcoxon rank sum test was used to analyze the
results. Differences were significant when P < 0.05. Symbols for
Heymann nephritic rats are: •—•, control; O---O, experimental
rats. The asterisk refers to P < 0.05.
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Table 2. Urine protein excretion and weights of saline-treated, and
DMSO-treated PHN rats: effect of reduction in DMSO dosage
N Day 0 Day 14 Day 28
Urine protein excretion,
mg124 hr
Control rats 10 184 34a 275 66
DMSO, 0.5 mg/g 10 93 33 113 29
P value <0.05 <0.05
Weight gain, g
Control rats 10 180 2a 285 6 355 9
DMSO, 0.5 mglg 10 186 3 283 6 354 5
P value NS NS NS
The values represent the mean SaM.
Table 3. Twenty-four hour urine protein excretion in normal Sprague-
Dawley rats treated with DMSOa
Day 0 Day 14 Day 21
Experimentalb (N = 12)
mg124 hr 4.2 1.5d 8.4 2.5 8.5 2.5
Controle (N = 12)
mg124 hr 3.2 1.0 11.1 4.2 11.2 3.3
The Wilcoxon rank sum test on paired samples was used to analyze
the results; there was no significant difference between the two groups
on days 0, 14, or 21.
"Experimental rats were given DMSO 3 ml of a 40% solution (5 mg/g
body wt) i.p. twice daily for 20 days.
Control rats were given saline in the same regimen.
d Results reflect the mean SEM.
Plasma values. Group 1 rats studied on day 21 had no
significant differences in BUN, creatinine, albumin, cholester-
ol, or triglyceride concentrations. However, the mean serum
globulin concentrations of the treated rats (2.0 0.1 g/dl, SD)
were significantly lower than control rats (1.6 0.2 g/dl, P <
0.01). Forty-two days after induction of PHN (3 weeks after
cessation of treatment), DMSO rats had lower concentrations
of BUN (14 2 vs. 17 2 mg/dl, P < 0.05), cholesterol (34 2
vs. 48 11 mgldl, P < 0.05) and triglyceride concentrations
(192 23 vs. 255 62 mg/dl, P < 0.05).
When group 2 rats were studied similarly on day 60 after
induction of PHN, the only finding consistent with those in
group I was a significant reduction in the serum triglyceride
concentrations of the treated rats: 153 8.5 mgldl versus 221
22 mg/dl for control rats (P < 0.02).
Serum IgG values of group 1 rats measured after 21 days of
treatment were not significantly different from control rats: 400
25 versus 445 41 mgldl (mean SD, experimental vs.
control rats). Three weeks after cessation of treatment, the
serum IgG levels of the DMSO rats were 397 15; this was not
significantly different from that of control rats: 363 25 mg/dl.
Rat serum antibody responses to infused rabbit antiserum
were measured in normal, saline-treated and DMSO-treated
rats 28 days after induction of PHN in the latter two groups
(Table 4). Endogenous and exogenous immune complexes
formed following the addition of antigen(s) were expected to be
precipitated by the added PEG [37]. Although the mean levels
of endogenous immune complexes in PHN rats were higher
than that of control rats, statistical differences between these
values could not be demonstrated. The quantity of immune
complexes formed was significantly different in normal rats
Table 4. Serologic immune responses of PHN rats with or without
DMSO treatment
Antigen(s)
added to rat
Protein precipitatesa
PHN rats
Saline controls DMSO exptNormal rats
serum (N = 5) (N = 11) (N = 10)
Saline 17.5 4.2 19.6 3.1
I
NS
23.1 1.8
I
Rabbit IgGb 15.5 2.9 53.0 6.9
I I
P<0.0l NS
L
P < 0.01
61.9 6.6
I
I
Rabbit serumc 32.6 1.0 51.5 3.5I
P<0.01 NS
L
P < 0.01
48.5 2.1
I
I
The values are expressed as mg proteinldl of rat serum (±sE).
b Endogenous precipitable protein = 1.2 0.2 mgldl (N = 3).
Endogenous precipitable protein = 14.4 2.1 mg/dI (N = 8).
versus PHN rats treated with saline or DMSO. There was no
significant difference between the control and DMSO-treated
PHN rats.
The serum complement values of control and treated rats
studied 2 and 6 days after induction of PHN (that is, treated for
1 day and 5 days) are shown in Table 5. There was a significant
reduction in CH5O activity of treated rats on day 1, but no other
significant changes were found.
Histological studies. Glomeruli from rats studied after 4 days
of treatment had significantly less fluorescence for C3 com-
pared with control rats (Table 5). No significant difference was
found for C3 deposits after 21 days of treatment. In contrast to
the C3 results, no significant differences were found at any time
between treated and control rats for glomerular rat and rabbit
IgG deposits.
Electron microscopic study examination revealed the occur-
rence of dense-electron deposits in the subepithelial space in
both control and treated animals. Although there seemed to be
fewer deposits and more new basement membrane formation in
the glomeruli of experimental rats, this could not be assessed by
statistical methods.
In vitro C3 fixation. A significant reduction in human C3
deposition was found on day 5 (Table 6). Addition of DMSO to
normal human serum prior to incubation of kidney slices from
saline-treated rats with PHN revealed a significant reduction of
staining when the concentration of DMSO was either 1 or 5%
but not when it was 0.1% (Table 6).
Toxicity. Toxic effects of DMSO were assessed in four ways:
weight gain, serum transaminases, renal function, and percent-
age mortality. Rats treated with DMSO did not gain weight as
well as control rats; catch-up growth occurred after DMSO was
discontinued (Table 7). Rats treated with 0.5 mglg of DMSO had
a significant decrease in proteinuria but no reduction in weight
gain. There was no significant difference between the serum
glutamic oxalate and serum glutamic pyruvate transaminases
after 21 days of treatment: SGOT for experimental rats was 128
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Table 5. Serum complement values in control and DMSO-treated rats in the heterologous phase of PHN
Day Animal studied
CH5O
U/mi
Alternate pathway
U/mi
C3
mg/di
I Control 51.6 3.4 (6)a 42.0 4.4 (6) 92 2.1 (6)
Treated 32.3 3.3 (6)b 32.3 5.8 (6) 95 4.3 (6)
5 Control 54.2 2.6 (6) 33.3 6.7 (6) 86 3.5 (6)
Treated 66.4 9.1 (5) 55.4 2.3 (6) 100 4.2 (5)
a The values reflect the mean SEM; the number of rats studied is in parentheses.
b P < 0.01 (Day 1 control vs. treated rats); no significant differences were found between any of the other pairs (control vs. treated).
Day2 Day 5 Day8
Experimental rats 0.2b 0.5 2.0
Control rats 0.5 1.5 2.2
pa NS <0.05 NS
In vitro fixation of human C3
Experimental rats 0.5d 0.6 1.5
Control rats 0.3 2.6 2.3
P NS <0.01 NS
In vitro fixation of human C3 after addition of DMSO to normal
human serum (NHS)
Fluorescence
NHS 3.0 d
NHS + 0.1% DMSO 3.0 <001NHS + 1.0% DMSO 1.7
NHS + 5.0% DMSO 0.8
Heat-inactivated NHS 1.0
Anti-human C3 alone 0
43 and control rats, 198 54; SGPT was 31 3 and 33 2,
respectively. There was no evidence of a deleterious effect on
renal function; in fact, BUN concentrations were often lower in
treated than in control rats. Two out of 80 rats treated with
DMSO died (2.5%); all control rats survived.
Discussion
A number of important advances have been made in under-
standing the pathogenesis of glomerular immune complex inju-
ry, especially with respect to "in situ" immune complex
formation [38] and the role of charge in the maintenance of
normal glomerular permselectivity [39—41] and the localization
of antigens in the glomerular basement membrane [42, 431.
These advances have offered insight into the pathogenesis of
membranous glomerulonephritis, the most common form of
nephrotic syndrome in adults [1—4], but contrast, however, with
the lack of progress concerning the treatment of membranous
glomerulonephritis [5—131. Moreover, there has been very little
progress in the treatment of experimental models of this entity
and the results have been controversial. Heymann, Hunter, and
Hackel in 1962 [44] found that treatment of rats with autologous
immune complex nephritis using cortisone, ACTH, or nitrogen
mustard before and while immunization was in progress, de-
creased the prevalence of renal disease. Lim and Spargo [19],
using the same model, treated rats with either cyclophospha-
DayO Day2l Day42
Experimental rats
Control rats (N =
(N = 12)
12)
184 2
184 3
254 5
288 7
360
348
7
10
Pa NS <0.01 NS
mide, 6-mercaptopurine, or methylprednisolone. However, in
this protocol, treatment was started only after the disease was
well established and none of these agents reduced protein
excretion. Bolton, Spargo, and Lewis [20] studied the effect of
cyproheptadine, an agent with antihistamine and antiserotonin
properties, on the development of proteinuria in rats with
chronic autologous immune complex glomerulopathy. These
investigators found that cyproheptadine delayed the onset of
proteinuria and decreased the quantity of protein excreted in
nephrotic rats.
In the above studies, the autologous model of Heymann
nephritis was used. Other investigators [17, 181 have treated
rats with the passive model of Heymann nephritis but when
using corticosteroids and azathioprine, were unsuccessful, or
were able to reduce protein excretion only if the animals were
pretreated [19].
We have used DMSO to treat rats with passive Heymann
nephritis because of successful results obtained in the treatment
of human and murine renal amyloidosis with DMSO [21—25].
Further, DMSO was proven valuable in the treatment of an
immunologically mediated disorder, such as experimental my-
asthenia gravis [26].
Experimental membranous nephropathy was produced by
using rabbit antibodies raised against rat brushborder mem-
branes. These highly antigenic membranes can be prepared in
pure form. Every rat given serum containing rabbit anti-rat
brushborder antibody had the characteristic findings of epi-
membranous glomerulonephritis 3 hr later. Ultrastructural ex-
amination revealed electron-dense deposits in the subepithelial
space and effacement of the adjacent epithelial foot processes.
Furthermore, the urinary protein excretion increased signifi-
cantly (15 mg124 hr vs. 1,6 mg124 hr in normal rats of the same
age). The day after administration of the serum, treatment with
DMSO was commenced; after 1 week of treatment, treated rats
excreted significantly less protein compared with control rats
given saline. Even after treatment was discontinued, the
DMSO-treated rats excreted less protein, although these results
were no longer significantly different. In view of these encour-
aging results, the dose of DMSO was increased and the duration
Table 6. Glomerular deposits of rat C3a Table 7. Weight gain (g) in rats treated with DMSO (group I )a
a The values represent the mean SEM.
, Student's I test was used.
a FITC goat-anti-rat C3, graded 0—4, was used.
b The value represents the mean of six slides.
Wilcoxon rank sum test was used.
d The value represents the mean of three slides.
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of therapy was prolonged to a month in a second group of rats.
Even more convincing results were obtained. The treated rats
excreted significantly less protein than control rats during the
course of treatment and this significant difference persisted
during the months after DMSO was discontinued.
Rats with membranous nephritis were boosted with the
specific anti-BBM serum (Protocol B) resulting in the excretion
of larger quantities of protein (45.6 mg/24 hr). Rats with
proteinuria produced in this way were treated 6 weeks after the
first induction of the disease at a time when the disease was
more advanced. Promising results were again obtained. There
was a significant reduction in proteinuria which occurred after 3
weeks of treatment with DMSO (Fig. 4). However, this differ-
ence was no longer present 3 weeks after cessation of treat-
ment. The experiment was repeated and practically the same
results were obtained.
The lack of a clear-cut clinicopathological correlation with
respect to glomerular deposits of IgG, or subepithelial deposits
as seen by electron microscopy was disappointing. This lack of
correlation is unfortunately a well known phenomenon in
nephrology, There was, however, a significant decrease in
fluorescence for C3 in the glomeruli of rats during week 1 of the
disease when treatment was started the day after induction of
passive Heymann nephritis. Furthermore, there was also a
reduction of in vitro fixation of human C3 by glomeruli from
rats treated with DMSO, These results suggest that DMSO may
be altering the configuration of one or other protein subunits in
the immune deposits thus preventing C3 deposition early in the
heterologous phase. It is unlikely that DMSO is acting through a
mechanism in which serum complement is being inactivated
because CH5O activity was only transiently reduced, alternate
pathway activity and serum C3 concentrations were unaffected,
and in vitro fixation of human C3 could only be reduced when
high concentrations of DMSO were added to the human serum
in which the slices were incubated. Salant et a! [45] have
provided evidence that complement may have an important role
in the pathogenesis of proteinuria in passive Heymann nephritis
and our findings suggest that DMSO may influence C3-depen-
dent proteinuria.
The serologic immune response of rats against the infused
rabbit anti-serum was measured with a modified Fan's assay in
which ammonium sulfate is substituted by polyethylene glycol
[37]. Comparing the values of protein precipitates in normal and
PHN rats, it was apparent that PHN rats did not have signifi-
cant amounts of endogenously circulating immune complexes.
As the induction of PHN in rats was accomplished with rabbit
antiserum, serologic responses of rats were assayed against
normal rabbit serum. In addition, since one of the active
components of the rabbit antiserum was rabbit IgG, serologic
responses of rats were also assayed against a rabbit IgG
preparation. Whereas PHN rats had serologic responses to both
rabbit serum and rabbit IgG, DMSO treatment did not affect the
levels of antibody responses.
It is unlikely that DMSO has only one mode of action. DMSO
also has a generalized immunosuppressive effect, especially
when used in the same doses as in the present study [46].
However, serum IgG, serum rat anti-rabbit immunoglobulin,
serum rat anti-rabbit serum, and C3 concentrations were not
depressed in treated rats and proteinuria was not reduced in rats
with nephrotoxic serum nephritis. Therefore, if DMSO were
indeed acting by inducing generalized immunosuppression, this
effect appears to be more specific for the Heymann rather than
the nephrotoxic serum model and may be indirect evidence
against the possibility that DMSO induces a generalized immu-
nosuppressive effect or immunological unresponsiveness.
An enormous burden of proof rests on any investigator who
purports to have found a drug which cures or ameliorates a
disease. In recognition of this, these studies were done ex-
tremely carefully and, wherever possible, the odds were loaded
against the DMSO groups. For example, after group 4 rats were
ranked according to their protein excretion, rats with the
highest mean protein excretion were assigned to the treatment
cohort. Nonrandom distribution of protein excretion posed an
additional problem, but no attempt was made to exclude any
rats from the study. If arbitrary limits had been set prior to
giving DMSO, it is possible that the results may have been even
more significant.
Addition of DMSO in large quantities to urine vitiated the
sulfono-salicylic acid's ability to determine the protein concen-
tration. Excretion of DMSO by rats is 80% complete by 24 hr
[47] and all urine collections were made 3 to 4 days after the last
dose of DMSO. Furthermore, the treated group 2 rats continued
to excrete significantly less protein up to 30 days after their last
doses of DMSO. In addition, urine protein was not significantly
reduced in nephrotoxic or normal rats treated with DMSO.
Much attention has been focused on the potential toxic side
effects of DMSO [48]. The lenses of these rats were not
examined, hemoglobinuria was not seen, and there was no
evidence of hepatotoxicity as judged by the results of the SGOT
and SGPT determinations. The main side effect of DMSO in this
study was a reduction in weight gain, which was followed on
cessation of treatment by catch-up growth. Furthermore, when
a much lower daily dose of DMSO was used, there was a
significant reduction in proteinuria without any effect on weight
gain. Two rats (2.5%) died immediately after receiving DMSO.
Death occurred in one as a result of intraperitoneal hemorrhage.
We have shown that DMSO reduces proteinuria in PHN, in
part, by its ability to alter glomerular C3 deposits in this model
of C3-dependent proteinuria. Further studies may reveal wheth-
er DMSO acts in additional ways by influencing yet other
immunological mechanisms and/or by restoring the normal
physico-chemical characteristics of the glomerular basement
membrane and/or by changing the synthesis of this membrane
and/or by altering the synthesis of renal prostaglandins [49—51].
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